XOMA

85 articles about XOMA

• XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

  11/5/2019

  XOMA Corporation reported its third quarter 2019 financial results.

• Agenus Closes $15 Million Partial Royalty Monetization With XOMA

  9/21/2018

  Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation

• 

  Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs

  1/26/2018

  The company burned through $1.2B and never brought a drug to market in its 37 years.
• 

  3 Biopharmas Worth Watching in 2018

  1/15/2018

  Here are three biopharma stocks worth keeping an eye on.

• XOMA Strengthens Leadership Team With Appointments of Chief Business Officer and General Counsel

  1/8/2018

  Dr. Datta and Mr. Hart will report to XOMA’s Chief Executive Officer, Jim Neal.

• 

  Top 6 Biotech Stocks of 2017

  12/20/2017

  When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
• 

  Top 3 Biotech Stocks That Rocked in 2017

  12/18/2017

  Biotech stocks rocked in 2017, at least a lot of them did.
• 

  Bay Area's XOMA Snags $240M Deal With Newly-Transformed Rezolute

  12/7/2017

  Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities under the license.

• XOMA Reports Third Quarter 2017 Financial Results

  11/7/2017

  XOMA made important progress positioning the Company for long-term strategic success.

• XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries

  10/4/2017

• XOMA Presents Positive Data From PTH1R Monoclonal Antibody Program

  4/18/2017

• XOMA Corporation To Present At The Piper Jaffray Healthcare Conference

  11/24/2014

• Berkeley's XOMA Corporation To Stop Testing Drug As Arthritis Treatment, Shares Plunge

  3/6/2014

• XOMA Corporation’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity In Phase 2B Study Of Treatment-Naïve Adults

  3/5/2014

• Domain Therapeutics Enters Into Collaboration With XOMA Corporation

  2/4/2014

• XOMA Corporation Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute

  4/10/2013

• XOMA Corporation Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome

  11/29/2012

• XOMA Corporation's Nails Hypertension Trial, Seeks to Sublicense Drug

  11/23/2012

• XOMA Corporation Lands Orphan Drug Status for Eye Disease Treatment

  8/24/2012

• Oncobiologics Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMA's Fully Human Antibody Libraries for Their Discovery Platform

  7/31/2012